Real-world data confirm Mvasi's safety as a cost-effective alternative to reference bevacizumab (Avastin) for treating ...

Number 5: Sarfaraz K. Niazi, PhD, argues that the FDA can accelerate biosimilar entry by changing guidance under the Biologics Price Competition and Innovation Act (BPCIA) without needing ...

Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, supports biosimilars for cost savings but foresees challenges ...

Biosimilars promise cost savings and improved patient access in Latin America, yet face significant regulatory and ...

The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and ...

Biosimilars face a potential void as biologics lose exclusivity, prompting urgent calls for policy reform and enhanced ...

Government price negotiations under the Inflation Reduction Act may hinder biosimilar development, impacting drug costs and patient access to affordable therapies.

Number 5: Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, supports biosimilars for cost savings but foresees challenges adopting an intravenous daratumumab biosimilar, preferring the more ...

Peter Pitts is president and co-founder of the Center for Medicine in the Public Interest. He also serves as a visiting professor at the University of Paris School of Medicine. Pitts is a former ...